Cara Therapeutics (CARA)
(Delayed Data from NSDQ)
$0.35 USD
-0.01 (-3.61%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $0.34 -0.01 (-3.63%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.35 USD
-0.01 (-3.61%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $0.34 -0.01 (-3.63%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Zacks News
Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of -4.00% and 359.84%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: GILD's Positive CHMP Nod, Regulatory Updates & More
by Zacks Equity Research
Key headlines in the biotech sector last week include Gilead getting positive CHMP opinion, Keryx plunging on merger news while Celgene and Amgen came out with pipeline updates.
Implied Volatility Surging for Cara Therapeutics (CARA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Cara Therapeutics (CARA) stock based on the movements in the options market lately.
Surging Earnings Estimates Signal Good News for Cara Therapeutics (CARA)
by Zacks Equity Research
Cara Therapeutics (CARA) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision in addition to having decent short-term momentum.
Here's Why Cara Therapeutics (CARA) Shares Plummeted 31% Today
by Megan Sanks
Shares of Cara Therapeutics (CARA) nosedived 31% Friday in morning trading after the company announced disappointing results on the CR845 oral medication from a phase 2b trial.
Cara Therapeutics (CARA) Shows Strength: Stock Adds 12.2 % in Session
by Zacks Equity Research
Cara Therapeutics, Inc. (CARA) was a big mover last session, as the company saw its shares rise over 12% on the day
Implied Volatility Surging for Cara Therapeutics (CARA) Stock Options
by Zacks Equity Research
Investors in Cara Therapeutics (CARA) need to pay close attention to the stock based on moves in the options market lately.
Cara Therapeutics (CARA) Stock Rises After Cr845 Trial Update
by Megan Sanks
Cara Therapeutics, Inc. (CARA) shares gained 10% in late morning trading following the recent evaluation of its trial for Cr845.
5 Top Performing Stocks of the Best ETF of Q1
by Sweta Killa
Inside the top performing stocks of biotech ETF that tops the list of the best performing ETFs of Q1.
Cara Therapeutics (CARA) Shows Strength: Stock Up 5.2%
by Zacks Equity Research
Cara Therapeutics, Inc. (CARA) shares rose above 5% in the last trading session.
Are Options Traders Betting on a Big Move in Cara Therapeutics, Inc. (CARA) Stock?
by Zacks Equity Research
Investors in Cara Therapeutics, Inc. (CARA) need to pay close attention to the stock as it has some of the highest implied volatility of all equity options today.
Cara Therapeutics (CARA) Worth Watching: Stock Jumps 8%
by Zacks Equity Research
Cara Therapeutics, Inc. (CARA) was a big mover last session, as the company saw its shares climb over 8% on the day.